Natural compounds for cancer treatment and prevention
Open accessAbstract
We describe here the main natural compounds used in cancer therapy and prevention, the historical aspects of their application and pharmacognosy. Two major applications of these compounds are described: as cancer therapeutics and as chemopreventive compounds. Both natural compounds, extracted from plants or animals or produced by microbes (antibiotics), and synthetic compounds, derived from natural prototype structures, are being used. We also focus on the molecular aspects of interactions with their recognized cellular targets, from DNA to microtubules. Some critical aspects of current cancer chemotherapy are also discussed, focusing on genetics and genomics, and the recent revolutionary theory of cancer: aneuploidy as the primum movens of cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Cancer chemoprevention using marine natural compounds has not been investigated in-depth and the preclinical and clinical data for this strategy remain scant, in spite of the robust chemical rationale.
“Although the National Cancer Institute provides researchers with the resources needed to better elucidate the role of food and nutrients in cancer prevention, cancer chemoprevention using marine natural compounds [16,24] has not been investigated in-depth and the preclinical and clinical data for this strategy remain scant, in spite of the robust chemical rationale [16].”
From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [16]
The Conclusions say that chemoprevention with natural compounds has a robust molecular rationale but scant preclinical and clinical data. Section 2 describes the sea as an almost unexplored source of anticancer agents and says few marine compounds have undergone evaluation. Neither passage specifically establishes that marine compounds have been insufficiently investigated for chemoprevention; the marine-specific claim combines two broader observations. (LLM, conf=0.86)
Experimental — accuracy not yet measuredSeveral pathways are proposed for kahalalide F with specific interactions with cell membrane proteins.
“Several pathways are proposed for kahalalide F with specific interactions with cell membrane proteins [16].”
From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [16]
Section 4.3 (From marine sources; page not provided) says preliminary evidence suggests kahalalide F interacts with membranes or proteins, but it does not specify cell-membrane proteins. Its statement about a mechanism involving several pathways refers instead to didemnin B and aplidine. (LLM, conf=0.88)
Experimental — accuracy not yet measuredNatural bioactive molecules exhibit cytotoxic effects by attacking macromolecules expressed by cancer cells, such as those in oncogenic signal transduction pathways.
“Natural bioactive molecules exhibit cytotoxic effects by attacking macromolecules expressed by cancer cells, such as those in oncogenic signal transduction pathways [16].”
From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [16]
Squalamine and neovastat are currently tested in phase II and III studies for antiangiogenic activity.
“Squalamine, neovastat, and LAF389 were investigated for their antiangiogenic activity where squalamine and neovastat are currently tested in phase II and III studies, respectively [16].”
From Marine Natural Products: A Source of Novel Anticancer Drugs (2019) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 137 · Cited by 780
Research works printed but not linked: 13
- Marshall KM, Matsumoto LL, Holden JA, Concepcion GP, Tasdemir D, Ireland CM, et al. The antineoplastic and novel Topoisomerase II mediated cyto- toxicity of neoamphimedine, a marine pyridoacridine. Biochem Pharmacol 2003;66:447-58.
- Holton RA, Somoza C, Kim HB, Liang F, Biediger RJ, Boatman PD, et al. First Total Synthesis of Taxol. J Am Chem Soc 1994;116:1597-9.
- Aapro MS, Conte P. Esteban González E. Trillet-Lenoir V Drugs 2007;67:657-67.
- Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier PJ. Med Chem 1991;34:992-8.
- Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemo-therapy agents. Annu Rev Med 1997;48:353-74.
- Conlin A, Fornier M, Hudis C, Kar S, Kirkpatrick P. Ixabepilone. Nat Rev Drug Discov 2007;6:953-4.
- Hudson MM, Weinstein HJ, Donaldson SS, Greenwald C, Kun L, Tarbell NJ, et al. J Clin Oncol 1993;11:1080-4.
- Robert J. Anthracyclines. Chapter 9. In: Schellens JHM, McLeod HL, Newell DR, editors. Cancer clinical pharmacol. Oxford University Press; 2005. p. 117-33.
- Zunino F, Capranico G. DNA topisomerasas II as the primary target of antitu- moral anthracyclines. Anticancer Drug Des 1990;5:307-17.
- Friche E, Skovsgaardt T, Nissen JI. Anthracycline resistance. Acta Oncol 1989;28:877-81.
- Kantarjian HM, O'Brien S, Anderlini P, Talpaz M. Treatment of myelogenous leukemia: current status and investigational options. Blood 1996;87:3069-81.
- Arnold JT, Wilkinson BP, Korytynski EA, Steel VE. Chemopreventive activity of Maharishi Amrit Kalash and related agents in rat tracheal epithelial and human tumor cells. Proc Am Assoc Cancer Res 1991;32:128-31.
- Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA, et al. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 2008;68:8031-8.
- Authors
- Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S.
- Affiliations
- University of Florence (IT)
- Tumour Institute of Tuscany (IT)
- Corresponding author
- Witort, Ewa
- Mini, Enrico
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 59
- Issue
- 6
- Pages
- 365-378
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2136460234
- Cited by
- 780
- References
- 137
- Citations by year
- 2026: 22 · 2025: 44 · 2024: 60 · 2023: 55 · 2022: 54 · 2021: 55 · 2020: 66 · 2019: 63 · 2018: 65 · 2017: 52 · 2016: 52 · 2015: 30 · 2014: 42 · 2013: 37 · 2012: 25
- FWCI
- 33.01
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- Pharmacological Research (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Funders
- Ente Cassa di Risparmio di Firenze
- Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN2007)
- Associazione Italiana per la Ricerca sul Cancro (PRIN 2007)
- Topics
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Medicinal Plant Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioactive natural compounds
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Phytochemical Studies and Bioactivities
- Keywords
- natural compounds, cancer chemotherapy, chemoprevention, pharmacognosy, phytochemicals, microbial natural products, DNA interaction, microtubule interaction, aneuploidy, cancer genomics, history of cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Phytogenic, Antioxidants, Biological Products, Humans, Phytotherapy, Neoplasms, Pharmacognosy, Anticarcinogenic Agents, Dietary Supplements
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
